AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24886382 — intervention group
Group type: EXPERIMENTAL
Intervention: New rehabilitation programme (structured goal-planning, motivational interviewing, self-help booklet, four follow-up telephone calls during the first five months)
Number of subjects: 6
Study 24886382 — intervention group
Group type: EXPERIMENTAL
Intervention: New rehabilitation programme
Number of subjects: 6
Study 24886382 — intervention group
Group type: COMPARATOR
Intervention: Current traditional rehabilitation programme
Number of subjects: 6
Study 22614776 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist assisted by a computer
Number of subjects: 726
Study 22614776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 726
Study 20305509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation for 2 months (group I, 48 eyes)
Number of subjects: 145
Study 20305509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation for 5 months (group II, 47 eyes)
Number of subjects: 145
Study 18376061 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 57
Study 18376061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16035203 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal-yogurt mixture
Number of subjects: 15
Study 16035203 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal-water slurry
Number of subjects: 15
Study 16035203 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal with yogurt (in vitro)
Number of subjects: 15
Study 16035203 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal without yogurt (control from previous study)
Number of subjects: 15
Study 11881903 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 primes presented in lexical decision tasks
Number of subjects: 0
Study 11881903 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition priming
Number of subjects: 0
Study 11881903 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic information
Number of subjects: 0
Study 10426346 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the lowest LVEF quartile
Number of subjects: 0
Study 10426346 — intervention group
Group type: COMPARATOR
Intervention: Patients in the highest LVEF quartile
Number of subjects: 0
Study 7473439 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative prenatal care program (8 visits with one of nine study providers)
Number of subjects: 549
Study 7473439 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care (13 visits with different providers)
Number of subjects: 549
Study 2265162 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (lidocaine 5% and prilocaine 5%) applied for 45 to 60 minutes prior to IV cannulation
Number of subjects: 0
Study 2265162 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied for 45 to 60 minutes prior to IV cannulation
Number of subjects: 0
Study 7442597 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofibrate (500 mg, sustained release, 1 capsule per day)
Number of subjects: 404
Study 31444082 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (mean OSI 7.05 ± 4.65)
Number of subjects: 106
Study 31444082 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical group (mean OSI 2.92 ± 1.88)
Number of subjects: 106
Study 31444082 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal OSI cutoff value of 3.2
Number of subjects: 106
Study 31444082 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between OSI and CDVA
Number of subjects: 106
Study 30095476 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic trans-abdominal preperitoneal (TAPP) repair
Number of subjects: 165
Study 30095476 — intervention group
Group type: COMPARATOR
Intervention: Open Lichtenstein repair (OL)
Number of subjects: 165
Study 26987409 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solutions (4%, 16%, 48%)
Number of subjects: 11
Study 26987409 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 11
Study 24790022 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic training using King-Devick remediation software
Number of subjects: 0
Study 24790022 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0
Study 22198979 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy for 3 nights starting the first night after stroke onset, with additional nights based on apnea-hypopnea index results.
Number of subjects: 50
Study 22198979 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy (excellent use)
Number of subjects: 50
Study 22198979 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy (some use)
Number of subjects: 50
Study 22198979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 50
Study 22198979 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 50
Study 22198979 — intervention group
Group type: COMPARATOR
Intervention: Nursing workload
Number of subjects: 50
Study 20635803 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 20
Study 20635803 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 20
Study 19127132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 9965
Study 17477205 — intervention group
Group type: EXPERIMENTAL
Intervention: High feedback concerning subjects' responsivity to the Cs+ during extinction
Number of subjects: 0
Study 17477205 — intervention group
Group type: COMPARATOR
Intervention: Low feedback concerning subjects' responsivity to the Cs+ during extinction
Number of subjects: 0
Study 12601101 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's Disease (PD) group
Number of subjects: 0
Study 12601101 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10580624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mupirocin calcium ointment 2% administered twice a day for 5 days followed by twice monthly applications.
Number of subjects: 24
Study 10580624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mupirocin calcium ointment 2%
Number of subjects: 24
Study 8718332 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trial
Number of subjects: 0
Study 8718332 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind trial
Number of subjects: 0
Study 8718332 — intervention group
Group type: EXPERIMENTAL
Intervention: Factorial designs
Number of subjects: 0
Study 1896813 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40
Study 1896813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6223584 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG (20 mg twice a week or 40 mg once a week) with MF protocol (mitomycin C + 5-fluorouracil)
Number of subjects: 514
Study 6223584 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG (20 mg twice a week or 40 mg once a week) with F protocol (tegafur)
Number of subjects: 514
Study 6223584 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG
Number of subjects: 514
Study 30826311 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole cream
Number of subjects: 48
Study 30826311 — intervention group
Group type: COMPARATOR
Intervention: Tolnaftate solution
Number of subjects: 48
Study 30696807 — intervention group
Group type: COMPARATOR
Intervention: Placebo aiTBS
Number of subjects: 45
Study 30696807 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aiTBS
Number of subjects: 45
Study 30696807 — intervention group
Group type: COMPARATOR
Intervention: Sham aiTBS
Number of subjects: 45
Study 27641510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (PPI), 20 mg once daily
Number of subjects: 270
Study 27641510 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (H2RA), 40 mg once daily
Number of subjects: 270
Study 26407169 — intervention group
Group type: EXPERIMENTAL
Intervention: Work rate set to exhaust 70% of W' for 10 minutes (TEN)
Number of subjects: 14
Study 26407169 — intervention group
Group type: EXPERIMENTAL
Intervention: Work rate set to exhaust 70% of W' for 3 minutes (THREE)
Number of subjects: 14
Study 23403717 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thyrotropin (rhTSH)
Number of subjects: 60
Study 23403717 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormone withdrawal (THW)
Number of subjects: 60
Study 21331064 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during pretreatment (≤ ‐1.15% below screening weight)
Number of subjects: 480
Study 21331064 — intervention group
Group type: COMPARATOR
Intervention: Weight stable (61% of participants)
Number of subjects: 480
Study 21331064 — intervention group
Group type: COMPARATOR
Intervention: Weight gain (≥ +1.15% above screening weight)
Number of subjects: 480
Study 19761718 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg film‐coated tablet of avosentan
Number of subjects: 26
Study 19761718 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg film‐coated tablet of avosentan
Number of subjects: 26
Study 19761718 — intervention group
Group type: COMPARATOR
Intervention: 10 mg avosentan in 20 ml solution for infusion
Number of subjects: 26
Study 17567349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce Laryngeal Mask
Number of subjects: 50
Study 17567349 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 50
Study 15319761 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustments with placebo medicine
Number of subjects: 192
Study 15319761 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxants with sham adjustments
Number of subjects: 192
Study 15319761 — intervention group
Group type: COMPARATOR
Intervention: Placebo medicine with sham adjustments
Number of subjects: 192
Study 11003931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic treatment guided by gastric intramucosal pH monitoring
Number of subjects: 34
Study 11003931 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 34
Study 8803753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicaval Wythenshawe technique (group A)
Number of subjects: 50
Study 8803753 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (group B)
Number of subjects: 50
Study 1389938 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of the 5 mu diameter particle
Number of subjects: 12
Study 1389938 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of the 2 mu diameter particle
Number of subjects: 12
Study 6208841 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (375 mg)
Number of subjects: 12
Study 6208841 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (660 mg)
Number of subjects: 12
Study 6208841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 12
Study 30169436 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (optimal dose of 40.5 mg, 1.00 mg/kg/day)
Number of subjects: 26
Study 30169436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30169436 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 26
Study 29565947 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy of the genicular nerves
Number of subjects: 60
Study 29565947 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesics
Number of subjects: 60
Study 1300213 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANOVA)
Number of subjects: 0
Study 1300213 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple pre‐post difference scores
Number of subjects: 0
Study 1300213 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome expressed as percentage of baseline
Number of subjects: 0
Study 23321182 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally once daily
Number of subjects: 322
Study 23321182 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg orally twice daily
Number of subjects: 322
Study 23321182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 20400412 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (40 mg/day or maximum tolerated dose)
Number of subjects: 144
Study 20400412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 17299464 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple sweet potato (PSP) beverage (200.3 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Number of subjects: 38
Study 17299464 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (1.7 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Number of subjects: 38
Study 15968232 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (started at 5 mg daily, titrated to a maximum of 40 mg daily)
Number of subjects: 27
Study 15968232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12675976 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus distraction
Number of subjects: 48
Study 12675976 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus focusing
Number of subjects: 48
Study 12675976 — intervention group
Group type: COMPARATOR
Intervention: Exposure alone
Number of subjects: 48
Study 10566623 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH
Number of subjects: 229
Study 10566623 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormone withdrawal
Number of subjects: 229
Study 10566623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation
Number of subjects: 229
Study 9027517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (Two-County study)
Number of subjects: 0
Study 9027517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (Florence programme)
Number of subjects: 0
Study 1905602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian pharmacokinetic dosing program
Number of subjects: 147
Study 1905602 — intervention group
Group type: COMPARATOR
Intervention: Dosing based on physician choice (Control)
Number of subjects: 147
Study 1905602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study 1905602 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 147
Study 1905602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost savings based on reduced length of stay
Number of subjects: 147
Study 6333518 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibacterial preparation
Number of subjects: 50
Study 6333518 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibacterial preparation (Control)
Number of subjects: 50
Study 6333518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis
Number of subjects: 50
Study 31264758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 31
Study 31264758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30420920 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy alcohol use
Number of subjects: 365
Study 30420920 — intervention group
Group type: EXPERIMENTAL
Intervention: Having relatives who use alcohol
Number of subjects: 365
Study 30420920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low education status
Number of subjects: 365
Study 30420920 — intervention group
Group type: EXPERIMENTAL
Intervention: Making local brews as a source of income
Number of subjects: 365
Study 30420920 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having had complications in previous pregnancies
Number of subjects: 365
Study 27199314 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine
Number of subjects: 20
Study 27199314 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 20
Study 24627416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) adherence in E‐ZES group
Number of subjects: 8709
Study 24627416 — intervention group
Group type: COMPARATOR
Intervention: Endeavor zotarolimus‐eluting stent (E‐ZES) without DAPT
Number of subjects: 8709
Study 24627416 — intervention group
Group type: COMPARATOR
Intervention: Cypher sirolimus‐eluting stent (C‐SES) without DAPT
Number of subjects: 8709
Study 24627416 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT with E‐ZES
Number of subjects: 8709
Study 24627416 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT with C‐SES
Number of subjects: 8709
Study 22057018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 61
Study 22057018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 20 mg
Number of subjects: 61
Study 22057018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 61
Study 22057018 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 61
Study 22057018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 22128453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60
Study 22128453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 60
Study 22128453 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 60
Study 17299108 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 8 weeks in obese group
Number of subjects: 42
Study 17299108 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 42
Study 17299108 — intervention group
Group type: COMPARATOR
Intervention: Obese group
Number of subjects: 42
Study 17299108 — intervention group
Group type: COMPARATOR
Intervention: Non-obese group
Number of subjects: 42
Study 17299108 — intervention group
Group type: EXPERIMENTAL
Intervention: AT IL‐18 mRNA content and plasma IL‐18 concentration
Number of subjects: 42
Study 17931761 — intervention group
Group type: EXPERIMENTAL
Intervention: Marlboro Lights
Number of subjects: 40
Study 17931761 — intervention group
Group type: COMPARATOR
Intervention: Marlboro Ultra
Number of subjects: 40
Study 15189919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 24
Study 15189919 — intervention group
Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 24
Study 15189919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 11303489 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 mg beta-carotene from DGLV (n=37, after 18 dropouts)
Number of subjects: 110
Study 11303489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg beta-carotene from sweet pumpkin (n=36, 18 dropouts)
Number of subjects: 110
Study 11303489 — intervention group
Group type: COMPARATOR
Intervention: Vegetables containing virtually no beta-carotene (control) (n=37, 18 dropouts)
Number of subjects: 110
Study 11303489 — intervention group
Group type: EXPERIMENTAL
Intervention: DGLV (4.4 mg beta-carotene)
Number of subjects: 110
Study 9340061 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen III (PIIIP) concentrations in bronchoalveolar lavage fluid (BALF)
Number of subjects: 24
Study 9340061 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen III (PIIIP) concentrations in BALF in patients in II radiological stage
Number of subjects: 24
Study 8257551 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6‐1.2 mg per day, sublingually)
Number of subjects: 44
Study 8257551 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.3‐0.9 mg per day, oral)
Number of subjects: 44
Study 3084315 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (7 mg before breakfast and 3.5 mg before supper)
Number of subjects: 22
Study 3084315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11688590 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional physical therapy
Number of subjects: 55
Study 11688590 — intervention group
Group type: COMPARATOR
Intervention: Reference group physical therapy (normalization of quality of movement)
Number of subjects: 55
Study 11688590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 31327689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenalidomide and dexamethasone
Number of subjects: 301
Study 31327689 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone
Number of subjects: 301
Study 28799076 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music intervention
Number of subjects: 60
Study 28799076 — intervention group
Group type: COMPARATOR
Intervention: Self-directed music intervention
Number of subjects: 60
Study 28799076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27401338 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched nutritional therapy (peptamen + glutamine)
Number of subjects: 48
Study 27401338 — intervention group
Group type: COMPARATOR
Intervention: Control group (peptamen)
Number of subjects: 48
Study 24641642 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 54
Study 24641642 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway Classic
Number of subjects: 54
Study 22532960 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual triple-headed toothbrush
Number of subjects: 200
Study 22532960 — intervention group
Group type: COMPARATOR
Intervention: Manual single-headed toothbrush
Number of subjects: 200
Study 19785609 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine with iontophoretic patch (100 microA cm(‐2))
Number of subjects: 0
Study 19785609 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine without iontophoresis (passive group)
Number of subjects: 0
Study 17589423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 80
Study 17589423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15607126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NAC 600 mg b.i.d. for 2 months
Number of subjects: 55
Study 15607126 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. for 2 months
Number of subjects: 55